1-Bromo-2-(3,4-diethylphenyl)ethane | 208989-20-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Bromo-2-(3,4-diethylphenyl)ethane
• 英文别名: bromo-2-(3,4-diethylphenyl)ethane；4-(2-Bromoethyl)-1,2-diethylbenzene
• CAS: 208989-20-2
• 化学式: C₁₂H₁₇Br
• 分子量: 241.171
• InChiKey: GPGLSSKLPVRDCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  4-[3-(三氟甲基)苯基]-1,2,3,6-四氢吡啶 、 1-Bromo-2-(3,4-diethylphenyl)ethane 在 potassium carbonate 作用下， 以 正丁醇 为溶剂， 反应 5.0h， 生成 1-[2-(3,4-diethylphenyl)-ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine
  参考文献：
  名称：

  Use of 4-substituted tetrahydropyridines for making medicines acting on TGF-&bgr;1

  摘要：

  该发明涉及使用化合物(I)的方法，用于制备用于增加循环、细胞和细胞外TGF-β1水平的药物组合物。

  公开号：

  US06342505B1
• 作为产物：
  描述：

  在 三乙基硅烷 、 三氟乙酸 作用下， 反应 4.0h， 生成 1-Bromo-2-(3,4-diethylphenyl)ethane
  参考文献：
  名称：

  Use of 4-substituted tetrahydropyridines for making medicines acting on TGF-&bgr;1

  摘要：

  该发明涉及使用化合物(I)的方法，用于制备用于增加循环、细胞和细胞外TGF-β1水平的药物组合物。

  公开号：

  US06342505B1

文献信息

• Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination
  申请人：Sanofi-Synthelabo

  公开号：US06344464B1

  公开（公告）日：2002-02-05

  The invention relates to the use of tetrahydropyridine derivatives of the formula in which: R1 is a halogen or a CF3, (C1-C4)alkyl or (C1-C4)alkoxy group; Y is a nitrogen atom or a CH group; Z′ and Z″ are each hydrogen or a (C1-C3)alkyl group, or one is hydrogen and the other is a hydroxyl group, or the two together are an oxo group; and Z is: a phenyl radical; a phenyl radical monosubstituted by a substituent X, X being: (a) a (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C7)carboxyalkyl, (C1-C4)alkoxycarbonyl(C1-C6)alkyl, (C3-C7)carboxyalkoxy or (C1-C4)alkoxycarbonyl(C1-C6)alkoxy group; (b) a group selected from (C3-C7)cycloalkyl, (C3-C7)cycloalkoxy, (C3-C7)cycloalkylmethyl, (C3-C7)cycloalkylamino and cyclohexenyl, it being possible for said group to be substituted by a halogen, hydroxy, (C1-C4)alkoxy, carboxy, (C1-C4)alkoxycarbonyl, amino or mono- or di-(C1-C4)alkylamino group; or (c) a group selected from phenyl, phenoxy, phenylamino, N—(C1-C3)alkyl-phenylamino, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulfonyl, phenylsulfinyl and styryl, it being possible for said group to be monosubstituted or polysubstituted on the phenyl group by a halogen, CF3, (C1-C4)alkyl, (C1-C4)alkoxy, cyano, amino, mono- or di-(C1-C4)alkylamino, (C1-C4)acylamino, carboxy, (C1-C4)alkoxycarbonyl, aminocarbonyl, mono- or di-(C1-C4)alkylaminocarbonyl, amino(C1-C4)alkyl, hydroxy(C1-C4)alkyl or halogeno(C1-C4)alkyl group; a phenyl radical disubstituted by a substituent R2, R2 being a halogen or a hydroxy, methyl, ethyl, (C3-C6)alkyl, (C1-C4)alkoxy or trifluoromethyl group, and by a substituent X, X being as defined above; a 1-naphthyl or 2-naphthyl radical; or a 1-naphthyl or 2-naphthyl radical substituted in the 5-, 6-, 7- and/or 8-positions by one or two hydroxy groups, one or two (C1-C4)alkoxy groups or a 6,7-methylenedioxy group; or Z″ is hydrogen and Z and Z′ are each independently an unsubstituted or mono-, di- or tri-substituted phenyl group, or a pharmaceutically acceptable salt and solvate thereof, for the preparation of pharmaceutical compositions intended for treating diseases which cause demyelination.

  该发明涉及以下公式的四氢吡啶衍生物的使用：其中：R1是卤素或CF3，(C1-C4)烷基或(C1-C4)烷氧基；Y是氮原子或CH基团；Z′和Z″分别是氢或(C1-C3)烷基，或一个是氢而另一个是羟基，或两者一起是氧代基；而Z是：苯基团；一个被取代基X单取代的苯基团，X是：(a) (C1-C6)烷基，(C1-C6)烷氧基，(C3-C7)羧基烷基，(C1-C4)烷氧羰基(C1-C6)烷基，(C3-C7)羧基烷氧基或(C1-C4)烷氧羰基(C1-C6)烷氧基团；(b) 选择自(C3-C7)环烷基，(C3-C7)环烷氧基，(C3-C7)环烷基甲基，(C3-C7)环烷基氨基和环己烯基的基团，该基团可以被卤素，羟基，(C1-C4)烷氧基，羧基，(C1-C4)烷氧羰基，氨基或单取代或双取代的(C1-C4)烷基氨基团取代；或(c) 选择自苯基，苯氧基，苯胺基，N—(C1-C3)烷基-苯胺基，苯甲基，苯乙基，苯羰基，苯硫醚，苯磺酰基，苯亚磺酰基和芳基的基团，该基团可以在苯基上被卤素，CF3，(C1-C4)烷基，(C1-C4)烷氧基，氰基，氨基，单取代或双取代的(C1-C4)烷基氨基，(C1-C4)酰氨基，羧基，(C1-C4)烷氧羰基，氨基羰基，单取代或双取代的(C1-C4)烷基氨基羰基，氨基(C1-C4)烷基，羟基(C1-C4)烷基或卤代(C1-C4)烷基团单取代或多取代；一个被取代基R2二取代的苯基团，R2是卤素或羟基，甲基，乙基，(C3-C6)烷基，(C1-C4)烷氧基或三氟甲基团，并且被定义如上的取代基X；一个1-萘基或2-萘基团；或一个在5、6、7和/或8位被一个或两个羟基，一个或两个(C1-C4)烷氧基或一个6,7-亚甲二氧基基团取代的1-萘基或2-萘基团；或Z″是氢，Z和Z′各自独立地是未取代或单取代，二取代或三取代的苯基团，或其药学上可接受的盐和溶剂，用于制备用于治疗导致髓鞘脱失的疾病的药物组合物。
• 1-Phenylalkyl-1,2,3,6-tetrahydropyridines for treating Alzheimer's
  申请人：Sanofi-Synthlabo

  公开号：US06034090A1

  公开（公告）日：2000-03-07

  The invention relates to compounds of the formula in which: Y is --CH-- or --N--; R.sub.1 is hydrogen, a halogen or a CF.sub.3, (C.sub.1 -C.sub.4)alkyl or (C.sub.1 -C.sub.4)alkoxy group; R.sub.2 is a methyl or ethyl group; R.sub.3 and R.sub.4 are each hydrogen or a (C.sub.1 -C.sub.3)alkyl; and X is: (a) a (C.sub.1 -C.sub.6)alkyl, a (C.sub.1 -C.sub.6)alkoxy, a (C.sub.3 -C.sub.7)carboxyalkyl, a (C.sub.1 -C.sub.4)alkoxy-carbonyl(C.sub.1 -C.sub.6)alkyl, a (C.sub.3 -C.sub.7)carboxyalkoxy or a (C.sub.1 -C.sub.4)alkoxycarbonyl-(C.sub.1 -C.sub.6)alkoxy; (b) a radical selected from (C.sub.3 -C.sub.7)cycloalkyl, (C.sub.3 -C.sub.7)cycloalkoxy, (C.sub.3 -C.sub.7)-cycloalkylmethyl, (C.sub.3 -C.sub.7)cycloalkylamino and cyclohexenyl, it being possible for said radical to be substituted by a halogen, hydroxyl, (C.sub.1 -C.sub.4)-alkoxy, carboxyl, (C.sub.1 -C.sub.4)alkoxycarbonyl, amino or mono- or di-(C.sub.1 -C.sub.4)-alkylamino; or (c) a group selected from a phenyl, phenoxy, phenylamino, N-(C.sub.1 -C.sub.3)alkyl-phenylamino, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulfonyl, phenylsulfinyl and styryl, it being possible for said group to be monosubstituted or polysubstituted on the phenyl group by a halogen, CF.sub.3, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, cyano, amino, mono- or di-(C.sub.1 -C.sub.4)alkyl-amino, (C.sub.1 -C.sub.4)acylamino, carboxyl, (C.sub.1 -C.sub.4)alkoxycarbonyl, aminocarbonyl, mono- or di-(C.sub.1 -C.sub.4)alkylaminocarbonyl, amino(C.sub.1 -C.sub.4)alkyl, hydroxy(C.sub.1 -C.sub.4)alkyl or halogeno(C.sub.1 -C.sub.4)alkyl; to a method of preparing them and to the pharmaceutical compositions containing them. These compounds have neurotrophic and neuroprotective activity.

  该发明涉及以下结构的化合物：其中：Y为--CH--或--N--; R.sub.1为氢、卤素或CF.sub.3、(C.sub.1-C.sub.4)烷基或(C.sub.1-C.sub.4)烷氧基；R.sub.2为甲基或乙基基团；R.sub.3和R.sub.4分别为氢或(C.sub.1-C.sub.3)烷基；X为：(a) (C.sub.1-C.sub.6)烷基、(C.sub.1-C.sub.6)烷氧基、(C.sub.3-C.sub.7)羧基烷基、(C.sub.1-C.sub.4)烷氧基-羰基(C.sub.1-C.sub.6)烷基、(C.sub.3-C.sub.7)羧基烷氧基或(C.sub.1-C.sub.4)烷氧羰基-(C.sub.1-C.sub.6)烷氧基；(b) 选自(C.sub.3-C.sub.7)环烷基、(C.sub.3-C.sub.7)环烷氧基、(C.sub.3-C.sub.7)-环烷基甲基、(C.sub.3-C.sub.7)环烷基氨基和环己烯基的基团，该基团可以被卤素、羟基、(C.sub.1-C.sub.4)-烷氧基、羧基、(C.sub.1-C.sub.4)烷氧羰基、氨基或单烷基氨基或双烷基氨基取代；或(c) 选自苯基、苯氧基、苯胺基、N-(C.sub.1-C.sub.3)烷基-苯胺基、苯甲基、苯乙基、苯羰基、苯硫醚、苯磺酰基、苯磺酰亚基和苯乙烯基的基团，该基团可以在苯基上被单取代或多取代卤素、CF.sub.3、(C.sub.1-C.sub.4)烷基、(C.sub.1-C.sub.4)烷氧基、氰基、氨基、单烷基氨基或双(C.sub.1-C.sub.4)烷基氨基、(C.sub.1-C.sub.4)酰氨基、羧基、(C.sub.1-C.sub.4)烷氧羰基、氨基羰基、单或双(C.sub.1-C.sub.4)烷基氨基羰基、氨基(C.sub.1-C.sub.4)烷基、羟基(C.sub.1-C.sub.4)烷基或卤代(C.sub.1-C.sub.4)烷基取代；以及制备这些化合物的方法和含有它们的药物组合物。这些化合物具有神经营养和神经保护活性。
• Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-beta 1
  申请人：——

  公开号：US20040157868A1

  公开（公告）日：2004-08-12

  The invention relates to the use of a compound of formula (I): 1 for the preparation of pharmaceutical compositions for increasing the circulating, cellular and extracellular levels of TGF-&bgr;1.

  本发明涉及使用公式（I）的化合物制备药物组合物以增加TGF-β1的循环、细胞和细胞外水平。
• Use of 4-substituted tetrahydropyridines for the manufacture of medicament s acting upon TGF-beta 1
  申请人：——

  公开号：US20020091143A1

  公开（公告）日：2002-07-11

  The invention relates to the use of a compound of formula (I): 1 for the preparation of pharmaceutical compositions for increasing the circulating, cellular and extracellular levels of TGF-&bgr;1.

  本发明涉及使用式(I)的化合物制备药物组合物，用于增加循环、细胞和细胞外基质中TGF-&bgr;1的水平。
• 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：Sanofi-Synthélabo

  公开号：EP0950048A1

  公开（公告）日：1999-10-20